<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39462250</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2398-9238</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Endocrinology, diabetes &amp; metabolism</Title><ISOAbbreviation>Endocrinol Diabetes Metab</ISOAbbreviation></Journal><ArticleTitle>Trends and Disparities in Coronary Artery Disease and Obesity-Related Mortality in the United States From 1999-2022.</ArticleTitle><Pagination><StartPage>e70010</StartPage><MedlinePgn>e70010</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70010</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/edm2.70010</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Almost half of the US adult population has obesity, which predisposes to atherosclerosis and can lead to poor prognosis in coronary artery disease (CAD). We aim to identify CAD and obesity-related mortality trends among adults in the United States stratified by age, sex, race and geographical location.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The CDC-WONDER database was used to extract death certificate data for adults aged ≥ 25 years. Crude mortality rates (CMR) and age-adjusted mortality rates (AAMRs) per 100,000 persons were calculated, and temporal trends were described by calculating annual percent change (APC) and the average APC (AAPC) in the rates using Joinpoint regression analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">From 1999 to 2022, a total of 273,761 CAD and obesity-related deaths were recorded in the United States. The AAMR increased consistently from 1999 to 2018 (APC: 4.3, 95% confidence interval (CI): 3.4-4.9) and surged thereafter till 2022 (APC: 11.4; 95% CI: 7.7-19.1). During the COVID-19 pandemic (2020-2022), AAMR almost doubled that of the rest of the study period. Additionally, the AAMR for males was nearly twice that of females. Non-Hispanic (NH) Blacks or African Americans displayed the highest AAMR, followed by NH Whites, Hispanic or Latino, and other NH populations. AAMRs showed minimal variation by census regions. Rural areas exhibited a higher AAMR (AAMR: 5.9, 95% CI: 5.8-5.9) than urban areas (AAMR: 4.4, 95% CI: 4.4-4.5).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We observed increasing trends in CAD and obesity-related deaths throughout the study period reaching a peak during the COVID-19 pandemic.</AbstractText><CopyrightInformation>© 2024 The Author(s). Endocrinology, Diabetes &amp; Metabolism published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Mushood</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9872-8224</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Javaid</LastName><ForeName>Hira</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Medicine, Allama Iqbal Medical College, Lahore, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shafiq</LastName><ForeName>Aimen</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nadeem</LastName><ForeName>Zain Ali</ForeName><Initials>ZA</Initials><Identifier Source="ORCID">0009-0008-5968-4538</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Allama Iqbal Medical College, Lahore, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahsan</LastName><ForeName>Areeba</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Foundation University Medical College, Islamabad, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nofal</LastName><ForeName>Abdullah</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0000-6919-2803</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Services Institute of Medical Sciences, Lahore, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Raheel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>National Heart &amp; Lung Institute, Imperial College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Royal Brompton Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alam</LastName><ForeName>Mahboob</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cardiology, The Texas Heart Institute, Baylor College of Medicine, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fudim</LastName><ForeName>Marat</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Duke Clinical Research Institute, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fonarow</LastName><ForeName>Gregg C</ForeName><Initials>GC</Initials><AffiliationInfo><Affiliation>Ahmanson-UCLA Cardiomyopathy Center, Division of Cardiology, University of California Los Angeles, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mamas</LastName><ForeName>Mamas A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Keele Cardiovascular Research Group, Centre for Prognosis Research, Keele University, Stoke-On-Trent, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Endocrinol Diabetes Metab</MedlineTA><NlmUniqueID>101732442</NlmUniqueID><ISSNLinking>2398-9238</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="Y">Obesity</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="Y">Coronary Artery Disease</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009026" MajorTopicYN="N">Mortality</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054624" MajorTopicYN="N">Health Status Disparities</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CDC WONDER</Keyword><Keyword MajorTopicYN="N">coronary artery disease</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">obesity</Keyword></KeywordList><CoiStatement>Dr. Fonarow reported receiving personal fees from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Eli Lilly, Johnson &amp; Johnson, Medtronic, Merck, Novartis and Pfizer outside the submitted work. Dr. Fudim reported receiving personal fees from Alleviant, Ajax, Alio Health, Alleviant, Artha, Audicor, Axon Therapies, Bayer, Bodyguide, Bodyport, Boston Scientific, Broadview, Cadence, Cardioflow, Cardionomics, Coridea, CVRx, Daxor, Deerfield Catalyst, Edwards LifeSciences, Echosens, EKO, Feldschuh Foundation, Fire1, FutureCardia, Galvani, Gradient, Hatteras, HemodynamiQ, Impulse Dynamics, Intershunt, Medtronic, Merck, NIMedical, NovoNordisk, NucleusRx, NXT Biomedical, Orchestra, Pharmacosmos, PreHealth, Presidio, Procyreon, ReCor, Rockley, SCPharma, Shifamed, Splendo, Summacor, SyMap, Verily, Vironix, Viscardia and Zoll; and receiving grants from the National Institutes of Health, Doris Duke, outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>27</Day><Hour>17</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>27</Day><Hour>17</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>27</Day><Hour>9</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39462250</ArticleId><ArticleId IdType="pmc">PMC11512744</ArticleId><ArticleId IdType="doi">10.1002/edm2.70010</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sanchis‐Gomar F., Perez‐Quilis C., Leischik R., and Lucia A., “Epidemiology of Coronary Heart Disease and Acute Coronary Syndrome,” Annals of Translational Medicine 4, no. 13 (2016): 256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4958723</ArticleId><ArticleId IdType="pubmed">27500157</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalen J. E., Alpert J. S., Goldberg R. J., and Weinstein R. S., “The Epidemic of the 20th Century: Coronary Heart Disease,” American Journal of Medicine 127, no. 9 (2014): 807–812.</Citation><ArticleIdList><ArticleId IdType="pubmed">24811552</ArticleId></ArticleIdList></Reference><Reference><Citation>Powell‐Wiley T. M., Poirier P., Burke L. E., et al., “Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association,” Circulation 143, no. 21 (2021): 973, 10.1161/CIR.0000000000000973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000973</ArticleId><ArticleId IdType="pmc">PMC8493650</ArticleId><ArticleId IdType="pubmed">33882682</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavie C. J., Milani R. V., and Ventura H. O., “Obesity and Cardiovascular Disease,” Journal of the American College of Cardiology 53, no. 21 (2009): 1925–1932.</Citation><ArticleIdList><ArticleId IdType="pubmed">19460605</ArticleId></ArticleIdList></Reference><Reference><Citation>Alizadehsani R., Khosravi A., Roshanzamir M., et al., “Coronary Artery Disease Detection Using Artificial Intelligence Techniques: A Survey of Trends, Geographical Differences and Diagnostic Features 1991–2020,” Computers in Biology and Medicine 128 (2021): 104095.</Citation><ArticleIdList><ArticleId IdType="pubmed">33217660</ArticleId></ArticleIdList></Reference><Reference><Citation>Raisi‐Estabragh Z., Kobo O., Mieres J. H., et al., “Racial Disparities in Obesity‐Related Cardiovascular Mortality in the United States: Temporal Trends From 1999 to 2020,” Journal of the American Heart Association 12, no. 18 (2023): e028409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10547286</ArticleId><ArticleId IdType="pubmed">37671611</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilmot K. A., O'Flaherty M., Capewell S., Ford E. S., and Vaccarino V., “Coronary Heart Disease Mortality Declines in the United States From 1979 Through 2011: Evidence for Stagnation in Young Adults, Especially Women,” Circulation 132, no. 11 (2015): 997–1002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4828724</ArticleId><ArticleId IdType="pubmed">26302759</ArticleId></ArticleIdList></Reference><Reference><Citation>Qamar A., Abramov D., Bang V., Chew N. W., Kobo O., and Mamas M. A., “Has the First Year of the COVID Pandemic Impacted the Trends in Obesity‐Related CVD Mortality Between 1999 and 2019 in the United States?,” International Journal of Cardiology Cardiovascular Risk and Prevention 21 (2024): 200248.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10999992</ArticleId><ArticleId IdType="pubmed">38590764</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E., Altman D. G., Egger M., et al., “The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies,” Journal of Clinical Epidemiology 61, no. 4 (2008): 344–349.</Citation><ArticleIdList><ArticleId IdType="pubmed">18313558</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingram D. D. and Franco S. J., “2013 NCHS Urban‐Rural Classification Scheme for Counties,” Vital and Health Statistics 2 166 (2014): 1–73.</Citation><ArticleIdList><ArticleId IdType="pubmed">24776070</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson R. N. and Rosenberg H. M., “Age Standardization of Death Rates: Implementation of the Year 2000 Standard,” National Vital Statistics Reports 47, no. 3 (1998): 16–20.</Citation><ArticleIdList><ArticleId IdType="pubmed">9796247</ArticleId></ArticleIdList></Reference><Reference><Citation>Joinpoint Regression Program, Version 5.1.0 , Statistical Methodology and Applications Branch, Surveillance Research Program (Bethesda, MD: National Cancer Institute, 2024).</Citation></Reference><Reference><Citation>Wang Y., Beydoun M. A., Min J., Xue H., Kaminsky L. A., and Cheskin L. J., “Has the Prevalence of Overweight, Obesity and Central Obesity Levelled Off in the United States? Trends, Patterns, Disparities, and Future Projections for the Obesity Epidemic,” International Journal of Epidemiology 49, no. 3 (2020): 810–823.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7394965</ArticleId><ArticleId IdType="pubmed">32016289</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer M. R. and Barton M., “Estrogens and Coronary Artery Disease,” in Advances in Pharmacology (Amsterdam, The Netherlands: Elsevier, 2016), 307–360.</Citation><ArticleIdList><ArticleId IdType="pubmed">27451102</ArticleId></ArticleIdList></Reference><Reference><Citation>Yahagi K., Davis H. R., Arbustini E., and Virmani R., “Sex Differences in Coronary Artery Disease: Pathological Observations,” Atherosclerosis 239, no. 1 (2015): 260–267.</Citation><ArticleIdList><ArticleId IdType="pubmed">25634157</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A., Gould M., Daniel A., Mangal R., and Ganti L., “Access to Healthcare in Rural Communities: A Bibliometric Analysis,” Health Psychology Research 11 (2023): 90615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10712557</ArticleId><ArticleId IdType="pubmed">38089642</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh G. K., Azuine R. E., Siahpush M., and Kogan M. D., “All‐Cause and Cause‐Specific Mortality Among US Youth: Socioeconomic and Rural‐Urban Disparities and International Patterns,” Journal of Urban Health: Bulletin of the New York Academy of Medicine 90, no. 3 (2013): 388–405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3665977</ArticleId><ArticleId IdType="pubmed">22772771</ArticleId></ArticleIdList></Reference><Reference><Citation>Saadatagah S., Varughese M. G., and Nambi V., “Coronary Artery Disease Risk Prediction in Young Adults: How Can We Overcome the Dominant Effect of Age?,” Current Atherosclerosis Reports 25, no. 6 (2023): 257–265.</Citation><ArticleIdList><ArticleId IdType="pubmed">37195598</ArticleId></ArticleIdList></Reference><Reference><Citation>Madhavan M. V., Gersh B. J., Alexander K. P., Granger C. B., and Stone G. W., “Coronary Artery Disease in Patients ≥ 80 Years of Age,” Journal of the American College of Cardiology 71, no. 18 (2018): 2015–2040.</Citation><ArticleIdList><ArticleId IdType="pubmed">29724356</ArticleId></ArticleIdList></Reference><Reference><Citation>Conraads V. M., Pattyn N., De Maeyer C., et al., “Aerobic Interval Training and Continuous Training Equally Improve Aerobic Exercise Capacity in Patients With Coronary Artery Disease: The SAINTEX‐CAD Study,” International Journal of Cardiology 179 (2015): 203–210.</Citation><ArticleIdList><ArticleId IdType="pubmed">25464446</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>